Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7573MR)

This product GTTS-WQ7573MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7573MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9227MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ5033MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ9079MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ10637MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ13673MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RC18
GTTS-WQ15532MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ882MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ8359MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hPAM4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW